Key Moments
- UBS began coverage of Pfizer with a Neutral rating and a $25 price target, citing continued revenue uncertainty.
- Meanwhile, analysts estimate that $15–20 billion of Pfizer’s annual revenue could be at risk from patent expirations over the next three years.
- Although UBS views Pfizer’s Metsera obesity deal positively, it says additional transactions will be needed to ease revenue pressure after 2028.
UBS Launches Coverage With Neutral Stance
UBS has taken a cautious stance on Pfizer Inc. Overall, the firm said recent efforts to expand the obesity portfolio support the long-term story. However, it added that these steps alone cannot offset a wave of patent expirations expected later this decade.
More specifically, coverage began with a Neutral rating and a $25 price target. At the same time, UBS pointed to ongoing uncertainty around future sales as several top drugs approach the end of exclusivity within the next three years.
Patent Cliff Poses Significant Revenue Risk
Meanwhile, investors are closely watching whether Pfizer can build a durable growth platform beyond its patent cliff. Compared with peers, UBS sees less clarity around the company’s post-exclusivity growth outlook.
Notably, UBS estimates that roughly $15–20 billion of annual revenue faces patent-related risk. These exposed products include Vyndaqel/Vyndamax, Eliquis, Ibrance, and Xtandi.
| Product | Risk Factor |
|---|---|
| Vyndaqel/Vyndamax | Patent expiry exposure |
| Eliquis | Patent expiry exposure |
| Ibrance | Patent expiry exposure |
| Xtandi | Patent expiry exposure |
| Total annual revenue at risk | $15–20 billion (UBS estimate) |
As a result, UBS struggles to identify enough near-term pipeline contribution to fully replace lost revenue after 2028. By contrast, management has outlined a more optimistic long-term growth outlook.
Obesity Strategy Seen as Helpful but Insufficient
On the positive side, UBS acknowledged the strategic value of Pfizer’s recent Metsera obesity transaction. Even so, analysts stressed that this deal alone is unlikely to restore sustainable growth.
Instead, the firm expects Pfizer to pursue further partnerships or acquisitions. In its view, these steps will be required to offset revenue losses tied to expiring patents.
Looking ahead, analysts highlighted Phase II obesity data expected in early 2026 as a potential catalyst. Still, they cautioned that there is no guarantee of success.
Valuation and Market Expectations
At present, Pfizer trades at roughly 8–9 times forward earnings and offers a dividend yield of 6–7%, according to UBS. Even so, the firm does not expect a meaningful re-rating in the near term.
Until investors gain more confidence in the pipeline, the stock is likely to remain range-bound. Ultimately, clear proof that new products can replace declining legacy sales will be needed to drive a sustained move higher.
TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover 
